Roche Holding AG ADR — CALQUENCE plus venetoclax · Chronic lymphocytic leukemia (CLL) and small lymph.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (9/5/25) through T+5. Run-up high $60.1 on 2/17/26, low $39.59 on 10/3/25 (T-120 to T-1). FDA decision 2/20/26. Historical price action, not a forecast.